Skip to main content

Part of the book series: Practical Issues in Geriatrics ((PIG))

  • 601 Accesses

Abstract

Older patients are the fastest growing and the most heterogeneous population. As many diseases occur more frequently with advancing age, so do cardiovascular diseases as well, and “cardiogeriatrics” has become an established term/specialty. Heart failure (HF) specifically is a highly prevalent disease in the older population. Most established standard treatments are effective in this group. However, the presence of comorbidities, polypharmacy, and frailty makes the management of HF in older patients more complex, and the benefit-risk of each treatment must be carefully weighed by a multidisciplinary team and shared with the patient and/or his/her relatives as part of a shared decision-making and a personalised care plan. We should keep in mind that we treat people, not diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Unlu O, Levitan EB, Reshetnyak E, Kneifati-Hayek J, Diaz I, Archambault A, et al. Polypharmacy in older adults hospitalized for heart failure. Circ Hear Fail. 2020;13(11):e006977.

    Google Scholar 

  2. Cherubini A, Laroche ML, Petrovic M. Mastering the complexity: drug therapy optimization in geriatric patients. Eur Geriatr Med [Internet]. 2021;12(3):431–4. https://doi.org/10.1007/s41999-021-00493-5.

  3. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J [Internet]. 2021;42(36):3599–726. https://academic.oup.com/eurheartj/article/42/36/3599/6358045.

  4. Jankowska EA, Vitale C, Uchmanowicz I, Tkaczyszyn M, Drozd M, Ponikowski P. Drug therapy in elderly heart failure patients. Eur Hear J Suppl. 2019;21:L8–L11.

    Google Scholar 

  5. Damy T, Chouihed T, Delarche N, Berrut G, Cacoub P, Henry P, et al. Diagnosis and management of heart failure in elderly patients from hospital admission to discharge: Position paper. 2021.

    Google Scholar 

  6. Ceia F, Fonseca C, Mota T, Morais H, Matias F, De Sousa A, et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail. 2002;4(4):531.

    PubMed  Google Scholar 

  7. Van Riet EES, Hoes AW, Limburg A, Landman MAJ, Van Der Hoeven H, Rutten FH. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail. 2014;16(7):772.

    PubMed  Google Scholar 

  8. Bleumink GS, Knetsch AM, Sturkenboom MCJM, Straus SMJM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure—the Rotterdam study. Eur Heart J. 2004;25(18):1614.

    PubMed  Google Scholar 

  9. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1624.

    PubMed  Google Scholar 

  10. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry. Eur J Heart Fail. 2017;19(12):1574.

    CAS  PubMed  Google Scholar 

  11. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682–8.

    PubMed  Google Scholar 

  12. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996–1004.

    PubMed  PubMed Central  Google Scholar 

  13. Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR, et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail. 2018;6(8):678.

    PubMed  PubMed Central  Google Scholar 

  14. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251.

    CAS  PubMed  Google Scholar 

  15. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22:1342–56.

    PubMed  Google Scholar 

  16. Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476.

    PubMed  Google Scholar 

  17. Buddeke J, Valstar GB, Van Dis I, Visseren FLJ, Rutten FH, Den Ruijter HM, et al. Mortality after hospital admission for heart failure: improvement over time, equally strong in women as in men. BMC Public Health. 2020;20(1):36.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Blais C, Dai S, Waters C, Robitaille C, Smith M, Svenson LW, et al. Assessing the burden of hospitalized and community-care heart failure in Canada. Can J Cardiol. 2014;30(3):352.

    PubMed  Google Scholar 

  19. Dai S, Walsh P, Wielgosz A, Gurevich Y, Bancej C, Morrison H. Comorbidities and mortality associated with hospitalized heart failure in Canada. Can J Cardiol. 2012;28(1):74.

    PubMed  Google Scholar 

  20. Guerra F, Brambatti M, Matassini MV, Capucci A. Current therapeutic options for heart failure in elderly patients. Biomed Res Int. 2017;2017:1483873. (Table 1).

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Hill E, Taylor J. Chronic heart failure care planning: considerations in older patients. Card Fail Rev. 2017;3(1):46.

    PubMed  PubMed Central  Google Scholar 

  22. Journal TP, Beezer BJ, Beezer J. Heart failure, older people and frailty diagnosis of heart failure and frailty can often be masked by other long-term conditions, making the delivery. 2021;(July 2019):1–16.

    Google Scholar 

  23. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.

    CAS  PubMed  Google Scholar 

  24. Mordi IR, Ouwerkerk W, Anker SD, Cleland JG, Dickstein K, Metra M, et al. Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF. Eur J Heart Fail. 2021;23(3):436.

    CAS  PubMed  Google Scholar 

  25. Japp D, Shah A, Fisken S, Denvir M, Shenkin S, Japp A. Mineralocorticoid receptor antagonists in elderly patients with heart failure: a systematic review and meta-analysis. Age Ageing. 2017;46:18–25.

    PubMed  Google Scholar 

  26. Ferreira JP, Rossello X, Eschalier R, McMurray JJV, Pocock S, Girerd N, et al. MRAs in elderly HF patients: individual patient-data meta-analysis of RALES, EMPAHSIS-HF, and TOPCAT. JACC Heart Fail. 2019;7(12):1012–21.

    PubMed  Google Scholar 

  27. Desai RJ, Patorno E, Vaduganathan M, Mahesri M, Chin K, Levin R, et al. Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. Heart. 2021;107(17):1407.

    CAS  PubMed  Google Scholar 

  28. Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36(38):2576.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet. 2020;396(10254):819.

    PubMed  Google Scholar 

  30. Fioretto P, Bruin T, Johnsson E, Ptaszynska A, Parikh S, List JF. Safety and efficacy of the SGLT2 inhibitor dapagliflozin in older patients with type 2 diabetes. Diabetologia. 2013;56.

    Google Scholar 

  31. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–45.

    CAS  PubMed  Google Scholar 

  32. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. FASTTRACK randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215.

    CAS  PubMed  Google Scholar 

  33. Düngen HD, Apostolović S, Inkrot S, Tahirović E, Töpper A, Mehrhof F, et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011;13(6):670.

    PubMed  PubMed Central  Google Scholar 

  34. Düngen HD, Musial-Bright L, Inkrot S, Apostolovic̈ S, Edelmann F, Lainščak M, et al. Heart rate following short-term beta-blocker titration predicts all-cause mortality in elderly chronic heart failure patients: insights from the CIBIS-ELD trial. Eur J Heart Fail. 2014;16(8):907.

    PubMed  Google Scholar 

  35. Yokote K, Terauchi Y, Nakamura I, Sugamori H. Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study. Expert Opin Pharmacother. 2016;17(15):1995.

    CAS  PubMed  Google Scholar 

  36. Kambara T, Shibata R, Osanai H, Nakashima Y, Asano H, Sakai K, et al. Use of sodium–glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus. Geriatr Gerontol Int. 2018;18(1):108.

    PubMed  Google Scholar 

  37. Trescoli Serrano C, Fajardo CJ, Arazo J, Tarazona-Santabalbina FJ. Real world safety and efficacy of SGLT-2 inhibitors in elderly type 2 diabetic patients. Innov Aging. 2017;1(Suppl 1):148.

    PubMed Central  Google Scholar 

  38. Yabe D, Shiki K, Suzaki K, Meinicke T, Kotobuki Y, Nishida K, et al. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes. BMJ Open. 2021;11(4):e045844.

    PubMed  PubMed Central  Google Scholar 

  39. Karagiannis T, Tsapas A, Athanasiadou E, Avgerinos I, Liakos A, Matthews DR, et al. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;174:108737.

    CAS  PubMed  Google Scholar 

  40. Armstrong PW, Roessig L, Patel MJ, Anstrom KJ, Butler J, Voors AA, et al. A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial. JACC Heart Fail. 2018;6(2):96–104.

    PubMed  Google Scholar 

  41. Screever EM, Meijers WC, van Veldhuisen DJ, de Boer RA. New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations. Expert Opin Pharmacother. 2017;18:645.

    CAS  PubMed  Google Scholar 

  42. Patel PH, Nguyen M, Rodriguez R, Surani S, Udeani G. Omecamtiv mecarbil: a novel mechanistic and therapeutic approach to chronic heart failure management. Cureus. 2021;13(1):e12419.

    PubMed  PubMed Central  Google Scholar 

  43. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC Heart Fail. 2020;8:329.

    PubMed  Google Scholar 

  44. Swedberg K. Stimulation of contractility in systolic heart failure. N Engl J Med. 2021;384(2):178.

    PubMed  Google Scholar 

  45. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J [Internet]. 2021;42(34):3227–3337. https://academic.oup.com/eurheartj/article/42/34/3227/6358713.

  46. Burnier M, Egan BM. Adherence in hypertension: a review of prevalence, risk factors, impact, and management. Circ Res. 2019;124(7):1124.

    CAS  PubMed  Google Scholar 

  47. OH, JFA, AB, GB, JPE, PF, et al. Guidelines for the management and diagnosis of congestive heart failure in the elderly adult. Rev Geriatr. 2004;29(8).

    Google Scholar 

  48. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure. Insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52(5):347–56.

    PubMed  Google Scholar 

  49. Detremerie C, De Backer T, Petrovic M. Polypharmacy and management of hypertension in frail elderly. Tijdschr Geneeskd. 2017;73(3).

    Google Scholar 

  50. Benetos A, Rossignol P, Cherubini A, Joly L, Grodzicki T, Rajkumar C, et al. Polypharmacy in the aging patient: management of hypertension in octogenarians. JAMA J Am Med Assoc. 2015;314(2):170.

    CAS  Google Scholar 

  51. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. J Hypertens. 2018;36:1956–2041.

    Google Scholar 

  52. Hanon O, Belmin J, Benetos A, Chassagne P, De Decker L, Jeandel C, et al. Consensus of experts from the French Society of Geriatrics and Gerontology on the management of heart failure in very old subjects. Arch Cardiovasc Dis. 2021;114(3):246.

    PubMed  Google Scholar 

  53. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Russ J Cardiol. 2020;25(5):3826.

    Google Scholar 

  54. Leung E, Wongrakpanich S, Munshi MN. Diabetes management in the elderly. Diabetes Spectrum. 2018;31:245.

    PubMed  PubMed Central  Google Scholar 

  55. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.

    PubMed  Google Scholar 

  56. Hindricks G, Potpara T, Dagres N, Bax JJ, Boriani G, Dan GA, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373–498.

    PubMed  Google Scholar 

  57. Carlisle MA, Fudim M, DeVore AD, Piccini JP. Heart failure and atrial fibrillation, like fire and fury. JACC Heart Fail. 2019;7:447–56.

    PubMed  Google Scholar 

  58. Gorenek B, Halvorsen S, Kudaiberdieva G, Bueno H, Van Gelder IC, Lettino M, et al. Atrial fibrillation in acute heart failure: a position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. Eur Heart J Acute Cardiovasc Care. 2020;9(4):348–57.

    PubMed  Google Scholar 

  59. Slawik J, Adrian L, Hohl M, Lothschütz S, Laufs U, Böhm M. Irregular pacing of ventricular cardiomyocytes induces pro-fibrotic signalling involving paracrine effects of transforming growth factor beta and connective tissue growth factor. Eur J Heart Fail. 2019;21(4):482.

    CAS  PubMed  Google Scholar 

  60. Kotecha D, Lam CSP, Van Veldhuisen DJ, Van Gelder IC, Voors AA, Rienstra M. Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J Am Coll Cardiol. 2016;68:2217.

    PubMed  Google Scholar 

  61. Smit MD, Moes ML, Maass AH, Achekar ID, Van Geel PP, Hillege HL, et al. The importance of whether atrial fibrillation or heart failure develops first. Eur J Heart Fail. 2012;14(9):1030.

    PubMed  Google Scholar 

  62. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J. 2005;26(13):1303.

    CAS  PubMed  Google Scholar 

  63. Mogensen UM, Jhund PS, Abraham WT, Desai AS, Dickstein K, Packer M, et al. Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2017;70(20):2490.

    PubMed  Google Scholar 

  64. Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121.

    PubMed  Google Scholar 

  65. Hanon O, Chaussade E, David JP, Boulloche N, Vinsonneau U, Fauchier L, et al. SAFIR cohort: one-year prospective follow-up of very old and frail patients treated with direct oral anticoagulant, rivaroxaban. Arch Cardiovasc Dis Suppl. 2020;12(1):115.

    Google Scholar 

  66. Grymonprez M, Steurbaut S, De Backer TL, Petrovic M, Lahousse L. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis. Front Pharmacol. 2020;11:583311.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the continued access registry. Circulation. 2011;123(4):417.

    PubMed  Google Scholar 

  68. Holmes DR, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1.

    PubMed  Google Scholar 

  69. Hess PL, Sheng S, Matsouaka R, DeVore AD, Heidenreich PA, Yancy CW, et al. Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the get with the guidelines—Heart Failure Program). Am J Cardiol. 2020;125(6):894.

    PubMed  Google Scholar 

  70. Sartipy U, Savarese G, Dahlström U, Fu M, Lund LH. Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. Eur J Heart Fail. 2019;21(4):471.

    PubMed  Google Scholar 

  71. Cho SW, Bin GH, Hwang JK, Chun KJ, Park KM, On YK, et al. Clinical features, predictors, and long-term prognosis of pacing-induced cardiomyopathy. Eur J Heart Fail. 2019;21(5):643.

    PubMed  Google Scholar 

  72. St. John Sutton M, Plappert T, Adamson PB, Li P, Christman SA, Chung ES, et al. Left ventricular reverse remodeling with biventricular versus right ventricular pacing in patients with atrioventricular block and heart failure in the BLOCK HF trial. Circ Heart Fail. 2015;8(3):510–8.

    PubMed  Google Scholar 

  73. Abdelrahman M, Subzposh FA, Beer D, Durr B, Naperkowski A, Sun H, et al. Clinical outcomes of his bundle pacing compared to right ventricular pacing. J Am Coll Cardiol. 2018;71(20):2319.

    PubMed  Google Scholar 

  74. Ravi V, Beer D, Pietrasik GM, Hanifin JL, Ooms S, Ayub MT, et al. Development of new-onset or progressive atrial fibrillation in patients with permanent his bundle pacing versus right ventricular pacing: results from the RUSH HBP registry. J Am Heart Assoc. 2020;9(22):e018478.

    PubMed  PubMed Central  Google Scholar 

  75. Fauchier L, Alonso C, Anselme F, Blangy H, Bordachar P, Boveda S, et al. Position paper for management of elderly patients with pacemakers and implantable cardiac defibrillators Groupe de rythmologie et stimulation cardiaque de la Société française de cardiologie et Société française de gériatrie et gérontologie. Gériatrie Psychol Neuropsychiatr du Viellissement. 2019;14(3):239.

    Google Scholar 

  76. Vaes B, Rezzoug N, Pasquet A, Wallemacq P, Van Pottelbergh G, Matheï C, et al. The prevalence of cardiac dysfunction and the correlation with poor functioning among the very elderly. Int J Cardiol. 2012;155(1):134.

    PubMed  Google Scholar 

  77. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, et al. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol. 1997;29(3):630.

    CAS  PubMed  Google Scholar 

  78. Osnabrugge RLJ, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, Lereun CM, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol. 2013;62(11):1002.

    PubMed  Google Scholar 

  79. Généreux P, Stone GW, O’Gara PT, Marquis-Gravel G, Redfors B, Giustino G, et al. Natural history, diagnostic approaches, and therapeutic strategies for patients with asymptomatic severe aortic stenosis. J Am Coll Cardiol. 2016;67:2263.

    PubMed  Google Scholar 

  80. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561–632.

    PubMed  Google Scholar 

  81. Afilalo J, Mottillo S, Eisenberg MJ, Alexander KP, Noiseux N, Perrault LP, et al. Addition of frailty and disability to cardiac surgery risk scores identifies elderly patients at high risk of mortality or major morbidity. Circ Cardiovasc Qual Outcomes. 2012;5(2):222–8.

    PubMed  Google Scholar 

  82. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597.

    CAS  PubMed  Google Scholar 

  83. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. Surv Anesthesiol. 2012;56(1):4.

    Google Scholar 

  84. Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366(18):1696.

    CAS  PubMed  Google Scholar 

  85. Bertrand PB, Schwammenthal E, Levine RA, Vandervoort PM. Exercise dynamics in secondary mitral regurgitation: pathophysiology and therapeutic implications. Circulation. 2017;135:297.

    PubMed  PubMed Central  Google Scholar 

  86. Dziadzko V, Clavel MA, Dziadzko M, Medina-Inojosa JR, Michelena H, Maalouf J, et al. Outcome and undertreatment of mitral regurgitation: a community cohort study. Lancet. 2018;391(10124):960.

    PubMed  PubMed Central  Google Scholar 

  87. Goliasch G, Bartko PE, Pavo N, Neuhold S, Wurm R, Mascherbauer J, et al. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. Eur Heart J. 2018;39(1):39.

    CAS  PubMed  Google Scholar 

  88. Ghoreishi M, Dawood MY, Gammie JS. Mitral valve surgery in elderly patients with mitral regurgitation: repair or replacement with tissue valve? Curr Opin Cardiol. 2013;28:164.

    PubMed  Google Scholar 

  89. Farid S, Ladwiniec A, Hernández-Sánchez J, Povey H, Caruana E, Ali A, et al. Early outcomes after mitral valve repair versus replacement in the elderly: a propensity matched analysis. Heart Lung Circ. 2019;28(2):314–9.

    PubMed  Google Scholar 

  90. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364(15):1395.

    CAS  PubMed  Google Scholar 

  91. Coats AJS, Anker SD, Baumbach A, Alfieri O, von Bardeleben RS, Bauersachs J, et al. The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. Eur Heart J. 2021;42(13):1254–69.

    PubMed  PubMed Central  Google Scholar 

  92. Ruf TF, Kreidel F, Tamm AR, Geyer M, Hahad O, Zirbs JC, et al. Transcatheter indirect mitral annuloplasty induces annular and left atrial remodelling in secondary mitral regurgitation. ESC Heart Fail. 2020;7(4):1400.

    PubMed  PubMed Central  Google Scholar 

  93. Geyer M, Keller K, Sotiriou E, Tamm AR, Ruf TF, Kreidel F, et al. Association of transcatheter direct mitral annuloplasty with acute anatomic, haemodynamic, and clinical outcomes in severe mitral valve regurgitation. ESC Heart Fail. 2020;7(6):3336.

    PubMed  PubMed Central  Google Scholar 

  94. Giallauria F, Di Lorenzo A, Parlato A, Testa C, Bobbio E, Vigorito C, et al. Individual patient data meta-analysis of the effects of the CARILLON® mitral contour system. ESC Heart Fail. 2020;7(6):3383.

    PubMed  PubMed Central  Google Scholar 

  95. Malik AH, Zaid S, Yandrapalli S, Shetty S, Aronow WS, Ahmad H, et al. Trends and outcomes with Transcatheter versus surgical mitral valve repair in patients ≥80 years of age. Am J Cardiol. 2020;125(7):1083.

    PubMed  Google Scholar 

  96. Del Val D, Ferreira-Neto AN, Wintzer-Wehekind J, Dagenais F, Paradis JM, Bernier M, et al. Early experience with transcatheter mitral valve replacement: a systematic review. J Am Heart Assoc. 2019;8(17):e013332.

    PubMed  PubMed Central  Google Scholar 

  97. Fiorilli PN, Herrmann HC, Szeto WY. Transcatheter mitral valve replacement: latest advances and future directions. Ann Cardiothorac Surg. 2021;10(1):85.

    PubMed  PubMed Central  Google Scholar 

  98. Reddy P, Shenoy C, Blaes AH. Cardio-oncology in the older adult. J Geriatr Oncol. 2017;8:308.

    PubMed  PubMed Central  Google Scholar 

  99. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945–60.

    PubMed  Google Scholar 

  100. Anker MS, Von Haehling S, Anker SD. Novel biomarkers in heart failure and cardio-oncology. Kardiol Pol. 2019;77:329.

    PubMed  Google Scholar 

  101. McDonagh T, Damy T, Doehner W, Lam CSP, Sindone A, van der Meer P, et al. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur J Heart Fail. 2018;20:1664.

    CAS  PubMed  Google Scholar 

  102. Mini P, Marc B, Fabien S, Chuzeville M. Prevalence of iron deficiency in patients aged 75 years or older with heart failure. J Geriatr Cardiol. 2018;15(11):682–6.

    PubMed  PubMed Central  Google Scholar 

  103. von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure: an overview. JACC Heart Fail. 2019;7:36–46.

    Google Scholar 

  104. Stugiewicz M, Tkaczyszyn M, Kasztura M, Banasiak W, Ponikowski P, Jankowska EA. The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. Eur J Heart Fail. 2016;18:762.

    PubMed  Google Scholar 

  105. Ponikowski P, Macdougall IC, Bohm M, Comin Colet J, Filippatos G, Roubert B, et al. An individual patient data meta-analysis of outcomes in 4 randomized double-blind trials of iron-deficient patients with HFrEF and renal dysfunction treated with IV ferric carboxymaltose. Eur J Heart Fail. 2017;19.

    Google Scholar 

  106. Peng Q, Yang Q. Risk factors and management of pulmonary infection in elderly patients with heart failure. Medicine (Baltimore). 2021;100(38):e27238.

    CAS  PubMed  Google Scholar 

  107. Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail. 2020;22:957.

    CAS  PubMed  Google Scholar 

  108. Rey JR, Caro-Codón J, Rosillo SO, Iniesta AM, Castrejón-Castrejón S, Marco-Clement I, et al. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020;22(12):2205.

    CAS  PubMed  Google Scholar 

  109. Vardeny O, Solomon SD. Influenza and heart failure: a catchy comorbid combination. JACC Heart Fail. 2019;7:118–20.

    PubMed  Google Scholar 

  110. Sokolski M, Trenson S, Sokolska JM, D’Amario D, Meyer P, Poku NK, et al. Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry, vol. 8. ESC Heart Fail; 2021. p. 4955.

    Google Scholar 

  111. Modin D, Jørgensen ME, Gislason G, Jensen JS, Køber L, Claggett B, et al. Influenza vaccine in heart failure. Circulation. 2019;139(5):575–86.

    PubMed  Google Scholar 

  112. Iyngkaran P, Liew D, Neil C, Driscoll A, Marwick TH, Hare DL. Moving from heart failure guidelines to clinical practice: gaps contributing to readmissions in patients with multiple comorbidities and older age. Clin Med Insights Cardiol. 2018;12:1179546818809358.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to T. L. De Backer .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

De Backer, T.L., Mangoni, A.A. (2023). Heart Failure. In: Cherubini, A., Mangoni, A.A., O’Mahony, D., Petrovic, M. (eds) Optimizing Pharmacotherapy in Older Patients. Practical Issues in Geriatrics. Springer, Cham. https://doi.org/10.1007/978-3-031-28061-0_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-28061-0_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-28060-3

  • Online ISBN: 978-3-031-28061-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics